IPPC Program

DAY ONE:    14  MARCH  2017

08:30-10:15 SESSION 1: KEYNOTE ADDRESS CHAIR: Bruno Santoni, PPTA
08:30-08:40 Opening Bruno Santoni, PPTA
08:40-08:55 Introduction by the PPTA Global Board Chairman David Bell, Grifols
08:55-09:20 A vision for health in the Czech Republic and in the EU Prof. Jaroslav Zverina, 1st Faculty of Medicine. Charles University, Prague
09:20-09:45 Blood Transfusion Service in the Czech Republic: Summary of plasma production and use of plasma pharmaceuticals in CZE Dr. Miloš Bohoněk, Central Military Hospital - Military University Hospital Prague
09:45-10:00 Discussions
10:00-10:15 HILFENHAUS AWARD 
10:15-11:00 BREAK 
11:00-12:30 SESSION 2: PRIMARY IMMUNODEFICIENCY DISEASE (PID) CARE CHAIR: Dr. Larisa Cervenakova, PPTA
11:00-11:25 PID care and awareness initiatives in Germany - current developments
Prof. Volker Wahn, University Hospital Charité - Berlin
11:25-11:50 Make use of the entire health care chain for optimal organization of PID care! Prof. Esther de Vries, Tilburg University
11:50-12:15 Perspectives in PID from Europe to Asia    Prof. Martin Van Hagen, Erasmus University Medical Center - Rotterdam
12:15-12:30 Discussions 
12:30-14:00 LUNCH  
14:00-15:35

SESSION 3: ANTI-D AND ERADICATION OF THE HEMOLYTIC DISEASE OF THE NEWBORN: AN UNFINISHED JOB?
CHAIR: Prof. Gérard Visser, University Medical Center Utrecht
14:00-14:20 Rh Disease: A major cause of child death and handicap worldwide Prof. Alvin Zipursky, Sick Kids Toronto
14:20-14:40 Hyperimmune plasma procurement: A challenge for the industry Dr. Kirsten Seidel, CSL Plasma
14:40-15:00 Challenges for the universal eradication of HDN: The CURhE coalition Prof. Vinod K. Bhutani, Stanford University
15:00-15:20 The industrial challenge Lawrence P. Guiheen, Kedrion
15:20-15:35 Discussions 
15:35-16:15 BREAK 
16:15-17:30

SESSION 4: HOW TO ENSURE BETTER NATIONAL ACCESS TO PLASMA PROTEIN THERAPIES? CHAIR: Jan M. Bult, PPTA

16:15-16:30 Romania: A challenging example Dr. Pană Adrian, Former Secretary of State in Romania
16:30-16:45 What do we need in France? Martine Pergent, French PID patient association (IRIS)
16:45-17:00 A novel approach to sustainable access to coagulation factors in Central and Eastern Europe Brian O'Mahony, European Haemophilia Consortium (EHC)
17:00-17:30 Panel Debate:  Identifying possible ways to maintain, develop, and optimize access to care 
 17:30-19:00 EVENING RECEPTION 

 

DAY TWO:    15  MARCH  2017

08:30-09:00
SESSION 5: SPONSORS SESSION
CHAIR: Bruno Santoni, PPTA
08:30-08:50 Supplier experience in supply chain risk management to meet patients’ needs    MERCK LOGO Purple RGB 01 Eric Youssef, Merck
08:50-09:00 Discussions 
09:00-10:30
SESSION 6: INTERNATIONAL DEVELOPMENTS CHAIR: Joshua Penrod, PPTA
09:00-09:20 Plasma protein consumption across countries: Contributing factors, data correlations and observations Patrick Robert, Marketing Research Bureau (MRB)
09:20-09:40 Access to care, contrasts across the world Dr. Pierre-Francois Falcou, PFF Consulting
09.40-10:00 Plasma products in India: Moving forward Dr. Ranjeet S. Ajmani, PlasmaGen Bioscience
10:00-10:20 Innovation: From local to global David Tsur, Kamada
10:20-10:30 Discussions    
10:30-11:00 BREAK
11:00-12:30
SESSION 7: REGULATORY ASPECTS CHAIR: Mary Gustafson, PPTA
11:00-11:25 NDDR and CDCS Programs expansion to Europe: Opportunities and obstacles John Delacourt, PPTA
11:25-11:50 New personal data protection regulation in the EU and potential applications to the plasma collection Cristiana Spontoni, Jones Day
11:50-12:15 Current Trends in Plasma Inspections Mag. Felix Patzak, Institute Surveillance, Department for Good Manufacturing Practice, Austrian Federal Office for Safety in Health Care
12:15-12:30 Discussions 
12:30-14:00 LUNCH
14:00-15:30
SESSION 8: HEALTH TECHNOLOGY ASSESSMENT (HTA) TO SUPPORT FAIR PATIENT ACCESS TO RARE DISEASE THERAPIES: ARE WE THERE YET?
CHAIR: Dr. Irina Odnoletkova, PPTA
14:00-14:25 Health-economic value of therapies to treat rare diseases Prof. Maarten Postma, University of Groningen
14:25-14:50 Reimbursement of medicinal products and the European HTA-harmonisation project: Are we on track? Prof. Philippe Van Wilder, Independent consultant in Access to Healthcare - SMART&BI; University of Brussels (ULB)
14:50-15:15 Patients adding value in HTA    Dr. Karen Facey , Evidence Based Health Policy Consultant - Honorary Research Fellow, University of Edinburgh, Scotland
15:15-15:30 Discussions                                   
15:30-15:35 CLOSURE OF IPPC 2017 
15:35-16:00 CLOSURE BREAK


[Program and speakers are subject to change]